Evaluation of Intra-Abdominal Fat in Patients With Type 2 Diabetes Using a Non-Invasive Method

Evaluation of Intra-Abdominal Fat Contents in Patients With Type 2 Diabetes Using a Novel Non-Invasive Method of Bioelectric Impedance

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01283113

Enrollment

110

Registered

2011-01-25

Start date

2010-08-01

Completion date

2017-01-01

Last updated

2026-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Obesity, Type 2 Diabetes

Keywords

Visceral Fat, Waist Circumference, Bioelectrical Impedance, Metabolic Syndrome, Obesity, Type 2 Diabetes

Brief summary

The main aim of this study is to compare 2 different measurements of visceral fat that can be easily used in clinical practice (waist circumference versus bioelectric impedance) in relation to known risk factors of coronary artery disease in a large cohort of patients with type 2 diabetes and with a BMI range between 20-45 kg/m2

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Established type 2 diabetes * Age 18 - 80 * Body mass index (BMI) between 20-45 Kg/m2. * Willing to undergo laboratory and anthropometric assessments.

Exclusion criteria

* The study will not include women who are pregnant, or are not using reliable birth control methods or who they think that they might be pregnant due to potential risk of fetal affection. * Subjects with known malignancy, treated or untreated will be excluded (except treated skin melanoma). * Subjects with major psychological problems or a major eating disorder will be excluded. * Subjects with heart Pacemaker or any other electronic devices attached to their body will be excluded. * Subjects with confirmed type 1 diabetes or positive anti GAD antibodies test will be excluded

Design outcomes

Primary

Measure	Time frame
Visceral fat level	immediate

Countries

United States

Contacts

PRINCIPAL_INVESTIGATOROsama Hamdy, M.D.

Joslin Diabetes Center

Outcome results